Cingulate Inc. (CING): R&D Expense
$9.77M
Year ended 2025-12-31
$8.52M
Trailing 12 months to 2026-06-30
+2.8%
3-year compound annual growth
+13.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.77M | +3.5% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $9.45M | -39.0% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $15.49M | +72.2% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $9.00M | +7.0% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $8.41M | +65.1% | 2023-03-10, From 2021-01-01 |
| 2020-12-31 | $5.09M | n/a | 2022-03-28, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cingulate Inc. (CING) | 2025-12-31 | $9.77M | +3.5% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $11.50M | -56.0% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $43.0K | -99.5% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $11.71M | -48.9% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $7.04M | -24.8% |
| Biovie Inc. (BIVI) | 2026-06-30 | $13.96M | +50.7% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $5.07M | -20.7% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.29M | n/a |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $10.29M | -44.9% |
Compare CING, CLRB, SYBX, RVPH side by side · Screen every company in Pharmaceutical Preparations ↗